Authors: Visani, G Milligan, D Leoni, F Chang, J Kelsey, S Marcus, R Powles, R Schey, S Covelli, A Isidori, A Litchman, M Piccaluga, PP Mayer, H Malagola, M Pfister, C

Citation: G. Visani et al., Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia, LEUKEMIA, 15(5), 2001, pp. 764-771

Authors: Tidefelt, U Liliemark, J Gruber, A Liliemark, E Sundman-Engberg, B Juliusson, G Stenke, L Elmhorn-Rosenborg, A Mollgard, L Lehman, S Xu, D Covelli, A Gustavsson, B Paul, C

Citation: U. Tidefelt et al., P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with p-glycoprotein-positive acute myeloid leukemia, J CL ONCOL, 18(9), 2000, pp. 1837-1844

Authors: Ben-Am, M Gemperli, B Covelli, A Burke, G

Citation: M. Ben-am et al., The pharmaceutical industry and oncology in Central and Eastern Europe, ANN ONCOL, 10, 1999, pp. 15-17

Authors: Covelli, A

Citation: A. Covelli, Modulation of multidrug resistance (MDR) in hematological malignancies, ANN ONCOL, 10, 1999, pp. 53-59